BWAY logo

BrainsWay Ltd. (BWAY)

$9.39

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BWAY

Market cap

$376815151

EPS

0.04

P/E ratio

65.3

Price to sales

9.04

Dividend yield

--

Beta

1.362996

Price on BWAY

Previous close

$10.11

Today's open

$9.57

Day's range

$9.25 - $9.71

52 week range

$7.14 - $17.40

Profile about BWAY

CEO

Hadar Levy

Employees

129

Headquarters

Jerusalem,

Exchange

NASDAQ Global Market

Shares outstanding

40129409

Issue type

American Depository Receipt

BWAY industries and sectors

Healthcare

Medical Equipment & Supplies

News on BWAY

BrainsWay: 3 Key Takeaways for Long-Term Investors

BrainsWay shipped 130 Deep TMS systems in the third quarter. U.S. insurance reimbursement for SWIFT reached 70 million covered lives.

news source

The Motley Fool • Nov 11, 2026

news preview

What Brainsway (BWAY) Said on Its Q3 Earnings Call

Brainsway NASDAQ: BWAY reported 34% revenue growth and a more than doubling of operating income in the third quarter of 2026, as shipments of its Deep TMS systems increased and reimbursement coverage expanded for its accelerated treatment protocol.

news source

MarketBeat • Nov 10, 2026

news preview

BrainsWay Ltd. (BWAY) Q3 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026

BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, November 10, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

news source

GlobeNewsWire • Oct 28, 2026

news preview

BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS™ in the treatment of patients suffering from obsessive compulsive disorder (OCD).

news source

GlobeNewsWire • Oct 26, 2026

news preview

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments

news source

GlobeNewsWire • Oct 19, 2026

news preview

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.

news source

GlobeNewsWire • Oct 13, 2026

news preview

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™

Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity

news source

GlobeNewsWire • Sep 8, 2026

news preview

Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?

The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Aug 27, 2026

news preview

Brainsway (BWAY) Upgraded to Buy: Here's Why

Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

news source

Zacks Investment Research • Aug 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BrainsWay Ltd.

Open an M1 investment account to buy and sell BrainsWay Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BWAY on M1